NASDAQ: CDXSCodexis Inc Stock
$2.86+0.03 (+1.06%)
Updated Apr 22, 2024
CDXS Price
$2.86
Fair Value Price
N/A
Market Cap
$201.07M
52 Week Low
$1.45
52 Week High
$4.91
P/E
-2.55x
P/B
2.32x
P/S
2.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$70.14M
Earnings
-$76.24M
Gross Margin
81.7%
Operating Margin
-108.59%
Profit Margin
-108.7%
Debt to Equity
0.58
Operating Cash Flow
-$53M
Beta
1.54
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CDXS Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDXS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CDXS is good value based on its book value relative to its share price (2.32x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
CDXS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CDXS due diligence checks available for Premium users.
Be the first to know about important CDXS news, forecast changes, insider trades & much more!
CDXS News
Valuation
CDXS fair value
Fair Value of CDXS stock based on Discounted Cash Flow (DCF)
Price
$2.86
Fair Value
-$3.31
Undervalued by
186.44%
CDXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.55x
Industry
16.21x
Market
41x
CDXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.32x
Industry
5.82x
CDXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDXS's financial health
Profit margin
Revenue
$26.6M
Net Income
-$7.2M
Profit Margin
-27.1%
CDXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDXS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$136.6M
Liabilities
$49.9M
Debt to equity
0.58
CDXS's short-term assets ($93.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDXS's short-term assets ($93.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDXS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CDXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
$1.1M
Financing
$0.0
CDXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDXS vs Biotech Stocks
Codexis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.